The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial

J Kolwelter; D Kannenkeril; P Linz; S Jung; AM Nagel; A Bosch; Christian Ott; P Bramlage; L Noh; M Schiffer; M Uder; S Achenbach; RE Schmieder

doi:10.1007/s00392-022-02119-7

The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial

J Kolwelter, D Kannenkeril, P Linz, S Jung, AM Nagel, A Bosch, Christian Ott (Co-Autor/-in), P Bramlage, L Noh, M Schiffer, M Uder, S Achenbach, RE Schmieder

Klinik für Innere Medizin 4 - Nephrologie und Hypertensiologie

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

19 Quellenangaben (Web of Science)

Originalsprache	Englisch
Fachzeitschrift	CLINICAL RESEARCH IN CARDIOLOGY : OFFICIAL JOURNAL OF THE GERMAN CARDIAC SOCIETY
DOIs	https://doi.org/10.1007/s00392-022-02119-7
Publikationsstatus	Veröffentlicht - 2022

Zugriff auf Dokument

10.1007/s00392-022-02119-7

Dieses zitieren

Kolwelter, J., Kannenkeril, D., Linz, P., Jung, S., Nagel, AM., Bosch, A., Ott, C., Bramlage, P., Noh, L., Schiffer, M., Uder, M., Achenbach, S., & Schmieder, RE. (2022). The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial. CLINICAL RESEARCH IN CARDIOLOGY : OFFICIAL JOURNAL OF THE GERMAN CARDIAC SOCIETY. https://doi.org/10.1007/s00392-022-02119-7

@article{e96ffc388d6647e98540dd5d3a26915c,

title = "The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial",

keywords = "STORAGE, HYPERTROPHY, HEALTH, FLUID",

author = "J Kolwelter and D Kannenkeril and P Linz and S Jung and AM Nagel and A Bosch and Christian Ott and P Bramlage and L Noh and M Schiffer and M Uder and S Achenbach and RE Schmieder",

note = "Ott: Paracelsus Med Univ, Dept Nephrol & Hypertens, Nurnberg, Germany",

year = "2022",

doi = "10.1007/s00392-022-02119-7",

language = "English",

journal = "CLINICAL RESEARCH IN CARDIOLOGY : OFFICIAL JOURNAL OF THE GERMAN CARDIAC SOCIETY",

issn = "1861-0692",

publisher = "Dietrich Steinkopff Verlag ",

}

Kolwelter, J, Kannenkeril, D, Linz, P, Jung, S, Nagel, AM, Bosch, A, Ott, C, Bramlage, P, Noh, L, Schiffer, M, Uder, M, Achenbach, S & Schmieder, RE 2022, 'The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial', CLINICAL RESEARCH IN CARDIOLOGY : OFFICIAL JOURNAL OF THE GERMAN CARDIAC SOCIETY. https://doi.org/10.1007/s00392-022-02119-7

TY - JOUR

T1 - The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial

AU - Kolwelter, J

AU - Kannenkeril, D

AU - Linz, P

AU - Jung, S

AU - Nagel, AM

AU - Bosch, A

AU - Ott, Christian

AU - Bramlage, P

AU - Noh, L

AU - Schiffer, M

AU - Uder, M

AU - Achenbach, S

AU - Schmieder, RE

N1 - Ott: Paracelsus Med Univ, Dept Nephrol & Hypertens, Nurnberg, Germany

PY - 2022

Y1 - 2022

KW - STORAGE

KW - HYPERTROPHY

KW - HEALTH

KW - FLUID

U2 - 10.1007/s00392-022-02119-7

DO - 10.1007/s00392-022-02119-7

M3 - Original Article

C2 - 36289063

SN - 1861-0692

JO - CLINICAL RESEARCH IN CARDIOLOGY : OFFICIAL JOURNAL OF THE GERMAN CARDIAC SOCIETY

JF - CLINICAL RESEARCH IN CARDIOLOGY : OFFICIAL JOURNAL OF THE GERMAN CARDIAC SOCIETY

ER -